1. Introduction {#sec1-genes-07-00095}
===============

Nicotine dependence (ND) is commonly assessed for cigarette smokers with DSM-IV criteria or a severity scale such as the Fagerstrom Test for Nicotine Dependence (FTND) \[[@B1-genes-07-00095]\]. FTND assesses the frequency of smoking, the number of cigarettes smoked and the urgency to smoke, and is widely used to index the severity of ND. Of the six questions assessed in FTND, the number of cigarettes smoked per day (CPD) has been shown to carry the highest genetic loading \[[@B2-genes-07-00095]\]. It has been hypothesized that the nicotinic acetylcholine receptors (nAChRs) play important roles in the development of ND and shows a strong association to CPD. The nAChR is named because its endogenous agonist is acetylcholine and the plant alkaloid nicotine also binds to these receptors. Neuronal nAChR include α2--α10 and β2--β4 subunits that are encoded by *CHRNAs* 2--10 and *CHRNBs* 2--4, respectively, whereas muscle-type nAChRs include α1, β1, γ, δ and ε subunits that are encoded by *CHRNA*1, *CHRNB*1, *CHRNG*, *CHRND* and *CHRNE*, respectively (reviewed by Zuo et al. \[[@B3-genes-07-00095]\]).

In this article, we reviewed the relationship between *CHRNs* and ND or CPD that were replicated across studies. We show that most significant risk variants (84%) for ND/CPD at the *CHRNs* are typically located in non-coding regions, and 95% of them have no direct effects on protein structure (see below). These non-coding genetic variants may have effects on the function of genes by altering the transcription, splicing or stability of the coding mRNAs. The association signals detected from the non-coding regions might be related to the roles of non-coding RNAs (ncRNAs) existing within, or proximate to, these regions, and thus these ncRNAs were explored in this study.

ncRNAs include long non-coding RNAs (LncRNAs) and small non-coding RNAs such as miRNAs, piRNAs, siRNAs, snoRNAs and rasiRNAs. Recent evidence suggests that LncRNAs are involved in a wide variety of cellular functions, including epigenetic silencing, transcriptional regulation, RNA processing and modification \[[@B4-genes-07-00095],[@B5-genes-07-00095],[@B6-genes-07-00095]\]; LncRNAs are also implicated in neural plasticity \[[@B7-genes-07-00095]\], neuropathological process \[[@B8-genes-07-00095]\], neurotransmission \[[@B9-genes-07-00095]\], and stress response \[[@B7-genes-07-00095]\]. Dysregulation of many LncRNAs has been found to contribute to substance use disorders including alcohol, nicotine, heroin and cocaine dependence. For example, *NEAT2*, an LncRNA regulating synapse formation \[[@B10-genes-07-00095]\], was up-regulated in alcoholics' brains \[[@B11-genes-07-00095]\]; *NEAT2,* *NEAT1,* *MIAT* and *MEG3* were up-regulated in the nucleus accumbens (NAc) of heroin abusers \[[@B12-genes-07-00095]\]; and *NEAT2, MIAT, MEG3* and *EMX2OS* were elevated in the NAc of cocaine abusers \[[@B12-genes-07-00095]\]. Smokers had dramatically elevated *H19* expression in airway epithelium \[[@B13-genes-07-00095]\]; demethylation of *H19* was correlated to chronic alcohol use in men \[[@B14-genes-07-00095]\]; and many LncRNAs mediated cocaine-induced neural plasticity in the NAc and conferred risk for cocaine dependence \[[@B8-genes-07-00095]\]. Together, evidence accumulates to support the hypothesis that LncRNAs contribute to the severity of ND, including the number of cigarettes smoked per day (CPD).

In addition to LncRNAs, piRNAs are also increasingly being studied for their roles in cellular functions. Numerous research indicates that piRNAs have important roles in modulating mRNA stability, regulating target mRNAs and translation \[[@B15-genes-07-00095]\], preserving genomic integrity \[[@B16-genes-07-00095]\], suppressing transposons \[[@B17-genes-07-00095]\], remodelling euchromatin, developmental regulation and epigenetic programming \[[@B18-genes-07-00095],[@B19-genes-07-00095]\]. Recent evidence suggests that piRNAs are abundant in the brain \[[@B17-genes-07-00095],[@B20-genes-07-00095],[@B21-genes-07-00095],[@B22-genes-07-00095],[@B23-genes-07-00095],[@B24-genes-07-00095],[@B25-genes-07-00095],[@B26-genes-07-00095],[@B27-genes-07-00095]\]. These piRNAs have unique biogenesis patterns and are associated with a neuronal Piwi protein. Thus, it has been hypothesized that piRNAs may potentially play roles in ND/CPD too. The LncRNAs and piRNAs that might regulate the effects of the replicated risk *CHRNs* on disease were analyzed in this study. This analysis is a necessary step towards identification of the missing regulatory pathways after a long history of attention to the coding mRNAs and other ncRNAs such as miRNAs.

In this article, we also reviewed the distribution of the nAChRs encoded by the replicated risk *CHRNs* in the human/mouse brain and then verified their expression in an independent sample of mouse brain. Furthermore, we explored the possible mechanisms underlying these replicated associations using a series of bioinformatics analyses.

2. Materials and Methods {#sec2-genes-07-00095}
========================

2.1. The Replicated Associations between Nicotinic Cholinergic Receptor Genes (CHRNs) and Nicotine Dependence/Cigarettes per Day (ND/CPD) and the Expression of Risk Genes in Brain {#sec2dot1-genes-07-00095}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In PubMed (<http://www.ncbi.nlm.nih.gov/pubmed>), we searched for the literature using the keywords "(nicotinic acetylcholine receptor OR nAChR OR nicotinic cholinergic receptor OR CHRN) AND (nicotine dependence OR nicotine addiction OR smoking OR cigarette)" and obtained 2463 reports (as of 19 September 2016). From these articles, we extracted the established associations between *CHRNs* and ND/CPD. We noticed that although most of the distinct *CHRNs* have been associated with ND/CPD, the replicable associations at single-point level by different studies are rare. We list such rare associations for six genes in three genomic regions from a total of 20 studies in [Table 1](#genes-07-00095-t001){ref-type="table"}.

Additionally, the distribution of the nAChRs encoded by the replicated risk *CHRNs* reported in the literature is illustrated in [Figure 1](#genes-07-00095-f001){ref-type="fig"} (<http://anatomy-bodychart.us/>) \[[@B28-genes-07-00095],[@B29-genes-07-00095],[@B30-genes-07-00095],[@B31-genes-07-00095],[@B32-genes-07-00095],[@B33-genes-07-00095],[@B34-genes-07-00095],[@B35-genes-07-00095],[@B36-genes-07-00095],[@B37-genes-07-00095],[@B38-genes-07-00095],[@B39-genes-07-00095],[@B40-genes-07-00095],[@B41-genes-07-00095],[@B42-genes-07-00095],[@B43-genes-07-00095],[@B44-genes-07-00095],[@B45-genes-07-00095],[@B46-genes-07-00095],[@B47-genes-07-00095],[@B48-genes-07-00095],[@B49-genes-07-00095],[@B50-genes-07-00095],[@B51-genes-07-00095],[@B52-genes-07-00095],[@B53-genes-07-00095]\].

2.2. Expression Correlation Analysis in Human Brain {#sec2dot2-genes-07-00095}
---------------------------------------------------

Based on our review ([Figure 1](#genes-07-00095-f001){ref-type="fig"}), all six replicated risk *CHRNs* are expressed in the midbrain that is enriched with dopaminergic neurons, and four *CHRNs* (i.e., *CHRNA4*, *CHRNA5, CHRNA6* and *CHRNB3*) are expressed in the striatum that is enriched with GABAergic terminals. These are two main neurotransmission systems that have been related to *CHRNs* in the literature (see [Section 4](#sec4-genes-07-00095){ref-type="sec"}: Discussion). We evaluated the mRNA expression levels of these genes and the dopaminergic and GABAergic receptors/enzymes in two independent brain tissue samples using Affymetrix Human ST 1.0 exon arrays (validated by qPCR). The first sample included ten human brain tissues extracted from 134 Europeans (UK Brain Expression Consortium (UKBEC) \[[@B74-genes-07-00095]\]). These 134 individuals were free of neurodegenerative disorders, and the ten brain tissues included cerebellar cortex, frontal cortex, temporal cortex, occipital cortex, putamen, thalamus, hippocampus, substantia nigra, intralobular white matter and medulla. The second sample included 93 autopsy-collected human frontal cortical tissues \[[@B75-genes-07-00095]\]. These 93 individuals included 55 male and 38 female Europeans, from 34 to 104 years old with an average of 74 ± 16 years. The postmortem intervals, i.e., the time from death to brain tissue collection, were 1.2--46 h with an average of 14.3 ± 9.5 h. These 93 individuals had no defined neuropsychiatric condition either. Correlations between expression of the risk *CHRNs* and expression of 25 dopaminergic and GABAergic receptor/enzyme genes were tested using Pearson correlation analysis for the first sample and generalized linear model (GLM) analysis for the second sample ([Table 2](#genes-07-00095-t002){ref-type="table"}). The 25 dopaminergic and GABAergic genes were *DRD1-5, TH, GABRA1-6, GABRB1-3, GABRD, GABRE, GABRG1-3, GABRR1-3, GABRP* and *GABRQ*. In the GLM, the expression levels of *CHRNs* served as dependent variable, and those of dopaminergic and GABAergic receptor genes as independent variable, by correcting for age, sex and postmortem interval. The directions of the correlations will be shown by the signs of correlation coefficients (r) or regression coefficients (β) ([Supplementary Tables S1 and S2](#app1-genes-07-00095){ref-type="app"}). α was set at 3.5 × 10^−5^ for the first sample because 10 brain regions, 25 dopaminergic and GABAergic genes and six *CHRNs* were evaluated, 6.9 × 10^−7^ for the second sample because 12,114 transcripts in the array and six *CHRNs* were evaluated.

2.3. Detection of Chrn mRNA Expression in Mouse Brains {#sec2dot3-genes-07-00095}
------------------------------------------------------

To verify the expression of the six replicated risk genes ([Figure 1](#genes-07-00095-f001){ref-type="fig"}), we examined their mRNA expression in mouse brains in our own samples. The levels of mRNA expression for the whole brain and in eight brain areas were examined, including the cortex, dorsal striatum, NAc, hippocampus, amygdala, midbrain, ventral tegmental area (VTA) and cerebellum ([Table 3](#genes-07-00095-t003){ref-type="table"}). The details for mouse strains, gene expression analysis, and calculation for standardized expression values (SEVs) and fold changes (FCs) were published previously \[[@B3-genes-07-00095]\].

2.4. Cis-Acting Genetic Regulation of Expression Analysis in Human Brain Tissues {#sec2dot4-genes-07-00095}
--------------------------------------------------------------------------------

To examine relationships between the replicated risk *CHRN* variants and local *CHRN* mRNA expression levels, we performed *cis*-acting expression of quantitative locus (*cis*-eQTL) analysis. Expression and genotype data of the six replicated risk *CHRN* genes in ten human brain tissues of the above first sample (i.e., 134 Europeans \[[@B74-genes-07-00095]\]) were evaluated. Differences in the distribution of mRNA expression levels between SNP genotypes were compared using a Wilcoxon-type trend test. *p*-values less than 0.05 were listed in [Table 4](#genes-07-00095-t004){ref-type="table"}. Significance level (α) was corrected by the numbers of tissues, genes and haplotype blocks, i.e., α = 2.8 × 10^−4^ = 0.05/(10 brain tissues × 6 genes × 3 independent haplotype blocks where the 19 replicated SNPs were located).

2.5. Bioinformatics Analysis {#sec2dot5-genes-07-00095}
----------------------------

The linkage disequilibrium (LD) between the replicated risk SNPs was assessed using online HapMap data. To verify the potential functions of these replicated risk SNPs, we predicted their functions using a series of bioinformatics analyses. We used UCSC Genome Browser data or other bioinformatics analysis software packages (e.g., FuncPred \[[@B76-genes-07-00095]\] or VE!P \[[@B77-genes-07-00095]\]) to see whether the risk SNPs are located in LncRNAs, in transcription factor binding sites (TFBS), in open chromatin regions, within methylated CpG islands, within copy number variations (CNVs) or in exonic splicing silencers (ESS) or enhancers (ESE). Additionally, Polyphen \[[@B78-genes-07-00095]\] and SIFT \[[@B79-genes-07-00095]\] were applied to predict the pathogenicity in order to see whether these risk SNPs affect protein function or structure, and MFOLD \[[@B80-genes-07-00095]\] was applied to predict whether these risk SNPs alter secondary RNA structure. The conservation of these risk SNPs across 17 species was also predicted \[[@B81-genes-07-00095]\]. The tertiary structure of the mutant and wild-type protein obtained by translation of each mutant gene was simulated using SWISS-MODEL software \[[@B82-genes-07-00095]\] so as to find the difference between them.

2.6. Long Non-Coding RNAs (LncRNA) and piRNA Analysis {#sec2dot6-genes-07-00095}
-----------------------------------------------------

There are tens of thousands of LncRNAs (\>200 nt) across the transcriptome \[[@B5-genes-07-00095],[@B83-genes-07-00095],[@B84-genes-07-00095]\], and more than half of them are expressed in the brain \[[@B85-genes-07-00095]\]. According to the positional relationship between LncRNAs and their associated protein-coding genes, LncRNAs can be classified as intergenic, intronic, antisense, sense overlapping, and bidirectional lncRNAs \[[@B86-genes-07-00095]\]. In this study, we extracted the LncRNAs close to, or within, the risk *CHRN* genes from the National Center for Biotechnology Information (NCBI) Gene database (<http://www.ncbi.nlm.nih.gov/gene>).

The RNAs interacting with the Piwi subfamily of proteins in Piwi/piRNA complex are named piRNAs. piRNAs are a class of small ncRNAs originally isolated from the mammalian germline, but recently they have also been detected in the brain \[[@B21-genes-07-00095],[@B22-genes-07-00095],[@B24-genes-07-00095]\]. Each species usually has hundreds of thousands of unique piRNA sequences. Mature piRNAs are short, single-stranded RNA molecules approximately 24--32 nucleotides in length. They are unevenly distributed in the genome, and usually cluster in some specific genomic loci. In this article, we searched for piRNAs within the risk *CHRN* genes from the piRNABank database \[[@B87-genes-07-00095]\].

3. Results {#sec3-genes-07-00095}
==========

3.1. Replicated Associations between CHRNs and ND/CPD ([Table 1](#genes-07-00095-t001){ref-type="table"}) {#sec3dot1-genes-07-00095}
---------------------------------------------------------------------------------------------------------

Replicated associations for ND/CPD were found at 19 SNPs in three genomic regions (*CHRNB3-A6*, *CHRNA5-A3-B4* and *CHRNA4*) in Europeans, Africans and Asians. They were replicated across at least three independent samples in at least two independent studies including genome-wide association studies (GWASs) \[[@B54-genes-07-00095],[@B62-genes-07-00095],[@B66-genes-07-00095],[@B68-genes-07-00095],[@B69-genes-07-00095],[@B71-genes-07-00095],[@B88-genes-07-00095]\] and candidate gene studies \[[@B55-genes-07-00095],[@B56-genes-07-00095],[@B57-genes-07-00095],[@B58-genes-07-00095],[@B59-genes-07-00095],[@B60-genes-07-00095],[@B61-genes-07-00095],[@B63-genes-07-00095],[@B64-genes-07-00095],[@B67-genes-07-00095]\], and some of them were verified by functional studies.

The associations for *CHRNA5-A3-B4* were most comprehensively studied and most robust; many of them were highly significant with *p* values below 10^−72^; and many of them were detected by high-impact unbiased GWASs. For example, Thorgeirsson et al. \[[@B71-genes-07-00095]\] (2008) and Liu et al. \[[@B68-genes-07-00095]\] (2010) reported associations between rs1051730 at *CHRNA*3 and smoking quantity (*p* = 5 × 10^−16^ and 1.7 × 10^−66^, respectively). This association has been replicated by numerous other GWASs \[[@B89-genes-07-00095],[@B90-genes-07-00095],[@B91-genes-07-00095]\] and candidate gene studies \[[@B56-genes-07-00095],[@B72-genes-07-00095],[@B92-genes-07-00095]\] and in a meta-analysis (*p* = 2.75 × 10^−73^ in the subjects of European ancestry) \[[@B57-genes-07-00095],[@B62-genes-07-00095],[@B66-genes-07-00095],[@B68-genes-07-00095]\]. Liu et al. \[[@B68-genes-07-00095]\] (2010) also reported associations between rs16969968 at *CHRNA*5 (*p* = 4.3 × 10^−65^) and rs6495308 at *CHRNA*3 (*p* = 5.8 × 10^−44^) and smoking quantity. These two SNPs were also associated with ND \[[@B92-genes-07-00095],[@B93-genes-07-00095]\]. rs16969968 was a non-synonymous, functional SNP \[[@B88-genes-07-00095]\] and was associated with experiencing pleasurable response upon first-time smoking, with current smoking status \[[@B94-genes-07-00095]\] and with ND \[[@B56-genes-07-00095],[@B61-genes-07-00095],[@B93-genes-07-00095]\], which was supported by some meta-analyses (*p* = 5.57 × 10^−72^ in European) \[[@B57-genes-07-00095],[@B62-genes-07-00095],[@B66-genes-07-00095],[@B68-genes-07-00095]\]. Berrettini et al. \[[@B72-genes-07-00095]\] (2008) also reported in a GWAS that rs6495308 at *CHRNA*3 was associated with CPD (*p* = 6.9 × 10^−5^). Additionally, a common haplotype at *CHRNA*5 and *CHRNA*3 increased risk across a series of ND-related phenotypes among European-origin populations, including ND \[[@B88-genes-07-00095],[@B89-genes-07-00095],[@B91-genes-07-00095],[@B92-genes-07-00095],[@B95-genes-07-00095]\], early-onset ND \[[@B96-genes-07-00095],[@B97-genes-07-00095]\], CPD \[[@B98-genes-07-00095]\], FTND score \[[@B89-genes-07-00095],[@B96-genes-07-00095]\], inability to quit when pregnant \[[@B99-genes-07-00095]\], serum cotinine (a nicotine metabolite) level \[[@B95-genes-07-00095],[@B100-genes-07-00095]\], and chronic obstructive pulmonary disease \[[@B101-genes-07-00095]\]. Finally, rare variant analysis showed that rare missense variants at conserved residues in *CHRNB*4 were associated with reduced risk of ND among African Americans \[[@B102-genes-07-00095]\]. Among these studies, at least five studies that identified peak SNPs rs16969968 and rs1051730 at *CHRNA5-A3-B4* as risk markers for ND or CPD were high-impact GWASs ([Table 1](#genes-07-00095-t001){ref-type="table"}) \[[@B62-genes-07-00095],[@B66-genes-07-00095],[@B68-genes-07-00095],[@B69-genes-07-00095],[@B71-genes-07-00095],[@B88-genes-07-00095]\].

Additionally, several other GWASs identified association peak for ND at *CHRNA*4 \[[@B64-genes-07-00095],[@B69-genes-07-00095],[@B89-genes-07-00095]\], a finding that has been widely replicated \[[@B56-genes-07-00095],[@B57-genes-07-00095],[@B64-genes-07-00095],[@B89-genes-07-00095],[@B103-genes-07-00095],[@B104-genes-07-00095]\]. Many other GWASs also showed an association of *CHRNB3--CHRNA6* with nicotine addiction \[[@B62-genes-07-00095],[@B89-genes-07-00095],[@B92-genes-07-00095],[@B105-genes-07-00095]\], which was replicated by many other candidate gene studies \[[@B56-genes-07-00095],[@B57-genes-07-00095],[@B58-genes-07-00095],[@B60-genes-07-00095],[@B64-genes-07-00095],[@B65-genes-07-00095]\]. This region was also associated with subjective response to tobacco use \[[@B106-genes-07-00095]\].

3.2. Distributions of Nicotinic Acetylcholine Receptors (nAChRs) Encoded by the Replicated Risk CHRNs in Brain ([Figure 1](#genes-07-00095-f001){ref-type="fig"}) {#sec3dot2-genes-07-00095}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------

The three replicated genomic regions including six genes are expressed in at least 18 brain areas. They are most commonly expressed in medial habenula, midbrain (including the VTA, substantia nigra, interpeduncular nucleus (IPN), lateral and medial geniculate bodies, and superior colliculus) and the mesolimbic system (VTA→NAc). They are also expressed in cortex, entorhinal cortex, striatum, thalamus, hippocampus, amygdala, locus coeruleus, brainstem nuclei and cerebellum. Specifically, *CHRNA5, CHRNA3* and *CHRNB4* are highly expressed in medial habenula. All six genes are expressed in the midbrain, although different genes have distinct densities in different midbrain areas. *CHRNA4* is expressed in the thalamus at the highest level. *CHRNA3* and *CHRNA5* are also expressed in the thalamus, with *α5* in low density. *CHRNA5* and *CHRNA3* are expressed in or around the hippocampus. Both have expression in amygdala and entorhinal cortex. *CHRNA3* also has a low level of expression in hippocampus. *CHRNA5* and *CHRNA4* are expressed in cortex. *CHRNA3* is also expressed in cingulate cortex and insular cortex at low density. *CHRNA5, CHRNA4, CHRNA6* and *CHRNB3* are expressed in striatum. *CHRNA6* is expressed in locus coeruleus, a noradrenergic nucleus with wide projections to cortical and subcortical structures \[[@B107-genes-07-00095]\]. *CHRNA3* is also expressed in brainstem nuclei. Finally, *CHRNA5* and *CHRNA3* are expressed in cerebellum.

3.3. All Six CHRN Genes Were Expressed in Human Brain and Their Expression Was Correlated with Dopaminergic or GABAergic Expression ([Table 2](#genes-07-00095-t002){ref-type="table"}, [Tables S1 and S2](#app1-genes-07-00095){ref-type="app"}) {#sec3dot3-genes-07-00095}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

These six *CHRN* genes were detected in ten human brain areas. In many areas, their expression was significantly correlated with the dopaminergic or GABAergic expression (*p* \< α) ([Table 2](#genes-07-00095-t002){ref-type="table"}). The correlation coefficients (0.358 ≤ \|r\| ≤ 0.920), regression coefficients (0.008 ≤ \|β\| ≤ 0.749) and *p* values (3.9 × 10^−42^ ≤ *p* ≤ 3.3 × 10^−5^) for these correlations are shown in the [Supplementary Tables S1 and S2](#app1-genes-07-00095){ref-type="app"}.

3.4. All Six Chrn Genes Were Expressed in Mouse Brain in Distinct Areas and at Different Levels, a Majority of Which Verified Previous Reports ([Table 3](#genes-07-00095-t003){ref-type="table"}) {#sec3dot4-genes-07-00095}
--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

We found that all six *Chrn* genes were expressed in mouse brain at different levels. All of these genes were expressed in the hippocampus, in which the gene with the most highly abundant expression (SEV \> 9) was *Chrna4* (SEV = 9.95). α4 mRNA was also abundant in other brain areas examined (SEV = 8.29--10.73), with 2.5-13.3-FCs in mRNA level compared to the expression base. Compared with other genes, α4 mRNA was also the most abundant in the whole brain and five other brain areas including cortex, striatum, NAc, amygdala and cerebellum ([Table 3](#genes-07-00095-t003){ref-type="table"}).

*Chrna5*, *Chrna3* and *Chrnb4* were expressed in multiple brain areas (SEV = 7.22--9.35), with a 1.2-5.1-FC in mRNA expression levels compared to the expression base (SEV = 7). *Chrna6* and *Chrnb3* were expressed in several areas (SEV = 7.11--10.37), among which a6 mRNA was the most abundant in the midbrain (FC = 10.4) and VTA (FC = 3.9) among all six *Chrns*. Many of these findings verified the previous reports described above.

3.5. The CHRN Variants May Regulate the Expression of CHRN Genes ([Table 4](#genes-07-00095-t004){ref-type="table"}) {#sec3dot5-genes-07-00095}
--------------------------------------------------------------------------------------------------------------------

*Cis-*eQTL analysis showed that 13 risk SNPs at *CHRNB3-CHRNA6* had nominally significant *cis-*acting regulatory effects on *CHRNB3* mRNA expression in cerebellar cortex and thalamus (*p* = 0.015--0.022 and 0.026--0.031, respectively), and on *CHRNA6* mRNA expression in frontal cortex and hippocampus (*p* = 0.042--0.043 and 0.027--0.033, respectively). Three risk SNPs at *CHRNA5-CHRNA3-CHRNB4* had nominally significant *cis-*acting regulatory effects on *CHRNA5* mRNA expression in almost all ten brain areas (5.1 × 10^−6^ ≤ *p* ≤ 0.034), and on *CHRNA3* mRNA expression in putamen (8.9 × 10^−4^ ≤ *p* ≤2.7 × 10^−3^). rs6495308 at this region also had nominally significant *cis*-acting regulatory effects on *CHRNB4* mRNA expression in occipital cortex and medulla (0.014 ≤ *p* ≤ 0.025). rs2236196 at *CHRNA4* had nominally significant *cis-*acting regulatory effects on *CHRNA4* mRNA expression in intralobular white matter and medulla (0.035 ≤ *p* ≤ 0.044). After Bonferroni correction (α = 2.8 × 10^−4^), the regulatory effects of the three risk SNPs at *CHRNA5-CHRNA3-CHRNB4* on *CHRNA5* mRNA expression remained significant in seven brain areas.

3.6. Bioinformatics Analysis ([Table 5](#genes-07-00095-t005){ref-type="table"}) {#sec3dot6-genes-07-00095}
--------------------------------------------------------------------------------

Of the 19 replicated risk variants, 15 SNPs at *CHRNB3-CHRNA6*, three SNPs at *CHRNA5-CHRNA3-CHRNB4*, and one SNP at *CHRNA4* are included. The 15 SNPs at *CHRNB3-CHRNA6* are all in high LD (D' \> 0.95) (<https://hapmap.ncbi.nlm.nih.gov/>). Among the 19 risk SNPs, 10 SNPs are located in LncRNAs that might regulate the gene expression. There are eight SNPs located in the TFBS. Most of them are located in the 5′ to *CHRNB3*. They may affect the local DNA conformation, and thereby influence the binding of transcription factors \[[@B108-genes-07-00095]\]. Two SNPs, i.e., rs4954 and rs2236196, are located in the open chromatin regions, which are often associated with regulatory factor binding. One SNP, rs1051730 at the exon 7 of *CHRNA3*, is located within a 234 bp CpG island, whose methylation status may affect the expression of *CHRNA3* \[[@B109-genes-07-00095]\]. rs16969968 (Asp398Asn) at the exon 5 of *CHRNA5* is located in an exonic splicing silencer or enhancer. Furthermore, seven SNPs are predicted to significantly or highly significantly alter the RNA secondary structures, including rs10958725, rs13273442, rs4736835, rs13277524, rs6474412 and rs4952 at *CHRNB3*, and rs16969968 at *CHRNA5*. Two SNPs are predicted to mildly alter the RNA secondary structures, including rs1955186 and rs7004381 at *CHRNB3*. They may affect the downstream activities of the RNA molecules \[[@B110-genes-07-00095]\]. rs16969968 is also predicted to be conservative across species. Finally, amino acid sequence alignment and three-dimensional computer space model verify that rs16969968 highly significantly alters protein structure and function ([Supplementary Figure S1](#app1-genes-07-00095){ref-type="app"}).

3.7. The LncRNAs and piRNAs Related to the Replicated Risk CHRNs {#sec3dot7-genes-07-00095}
----------------------------------------------------------------

The LncRNAs proximate to each gene are listed in [Table 6](#genes-07-00095-t006){ref-type="table"}. One sense LncRNA 37 kb to *CHRNB4* is a large intergenic non-coding RNA (LincRNA), with a length of 35 kb; two others overlapping with *CHRNB3* and *CHRNA4* are antisense LncRNAs, with lengths of 11 kb to 22 kb. The annotated piRNAs mapping within the two replicated *CHRN* gene regions are listed in [Table 7](#genes-07-00095-t007){ref-type="table"}. These piRNAs show a size distribution between 26 and 31 nt.

4. Discussion {#sec4-genes-07-00095}
=============

Replicated associations for ND/CPD were found at 19 SNPs in three genomic regions (*CHRNB3-A6*, *CHRNA5-A3-B4* and *CHRNA4*). Many of these associations are highly replicable across studies, highly significant, verified by functional studies, and supported by bioinformatics analysis, and thus are very robust. Interestingly, these three replicated loci were just the top three peak risk loci for ND identified by a GWAS meta-analysis using a large sample size of 17,074 \[[@B69-genes-07-00095]\]. We believe that *CHRNB3-A6*, *CHRNA5-A3-B4* and *CHRNA4* play important roles in the susceptibility to ND/CPD. Mechanisms underlying these roles may be related to the brain areas where the risk genes are expressed, the specific functions of the risk variants, or the regulatory pathways for the expression of these risk genes.

All replicated risk genes were expressed in human/mouse brain regions, which was verified at the mRNA level in our independent samples of both human and mouse brains. Many of these brain areas are important for the development of drug dependence \[[@B111-genes-07-00095]\]. Functional data have shown changes in nicotine intake following manipulations of α5\*, α3\* and β4\* nAChRs in the medial habenula, supporting that medial habenula could contribute to the reinforcing effect of nicotine \[[@B28-genes-07-00095]\]. Many areas in midbrain are enriched in dopaminergic neurons, including VTA (where all six replicated risk genes were expressed) and substantia nigra (β3\* and β4\*). We demonstrated that the mRNA expression of six *CHRNs* was correlated with the expression of dopaminergic receptor/enzyme genes in ten brain areas. Thus, the *CHRN* receptors in these areas may modulate dopamine release, and contribute to the reinforcing effect of nicotine. Several pathways in the midbrain, e.g., habenula-IPN pathway (α5\*, α3\* and β4\*) and VTA-NAc pathway (i.e., mesolimbic system; α5\*, α3\* and α4\*), are also critical to drug-induced reward responses. The thalamus plays a major role in relaying and transforming information to the cortex and in turn modulates cortical outputs. Imaging studies in humans implicated the thalamus in cognitive control \[[@B112-genes-07-00095]\], a process frequently compromised in individuals with addiction \[[@B113-genes-07-00095]\]. Nicotine binding to α4\* nAChRs in the human thalamus is very high in most thalamic nuclei, especially in the lateral dorsal, the medial geniculate, lateral geniculate and anterior nuclei. Striatum (α5\*, α4\*, α6\* and β3\*) receives dopaminergic input to the GABAergic medium spiny neurons. We demonstrated that the mRNA expression of six *CHRNs* was correlated with the expression of GABA receptor genes, supporting that nicotine stimulation of dopamine and GABA terminals in striatum may facilitate the release of these neurotransmitters. The locus coeruleus (α6\*) is the principal site for brain synthesis of norepinephrine (noradrenaline). This nucleus may be involved in physiological responses to stress and panic, and some symptoms of ND. Finally, the hippocampus, amygdala, cortex including entorhinal cortex, and cerebellum are involved in reward, learning, motor co-ordination, memory and/or emotion. Nicotine may direct information flow through the neural circuits via the activation of α5\*, α4\* and α3\* in these areas.

Our *cis*-eQTL and bioinformatics analyses provided additional evidence to support the previous findings that these replicated risk SNPs were functional \[[@B114-genes-07-00095],[@B115-genes-07-00095],[@B116-genes-07-00095]\]. They might influence the transcription, expression and splicing of the risk genes; they might alter the RNA secondary structure and thus affect the downstream activities of the RNA molecules; or they might even alter the structure and function of the proteins encoded by these risk genes. This analysis supports the roles of *CHRNs* in ND/CPD.

The sense LincRNA usually collaborates with chromatin modifying proteins (PRC2, CoREST and SCMX) to regulate expression of proximate genes \[[@B117-genes-07-00095]\]. Accordingly, we can postulate that the LincRNA XR_932509.1 might potentially regulate the expression of the *CHRNB4* and might be functional components of the pathways through which the *CHRNB4* variants influence risk for ND/CPD. The other two antisense-overlapping LncRNAs, i.e., XR_949716.1 and NR_110634.1, might use diverse transcriptional and post-transcriptional mechanisms \[[@B118-genes-07-00095],[@B119-genes-07-00095]\] to regulate *CHRNB3* and *CHRNA4* to play roles in ND/CPD.

The piRNAs in brain usually show unique biogenesis patterns and predominantly nuclear localization \[[@B20-genes-07-00095]\]. The influence of piRNAs on disease might depend on the neurotransmitters/genes they interact with or the brain areas they are expressed in. For example, the piRNAs may have robust sensitivity to serotonin, a neurotransmitter with important roles in learning and memory and widely implicated in the etiology of many mental disorders \[[@B18-genes-07-00095],[@B20-genes-07-00095]\]. The Piwi/piRNA complex may facilitate serotonin-dependent methylation of a conserved CpG island in the promoter of *CREB2*, the major inhibitory constraint of memory, leading to enhanced long-term learning-related synaptic facilitation \[[@B20-genes-07-00095]\]. Some piRNAs expressed in hippocampal neurons may influence dendritic spine morphogenesis \[[@B21-genes-07-00095]\]. For instance, piRNAs may target Astrotactin, which has been implicated in neuronal migration \[[@B120-genes-07-00095]\] or regulate genes to control nervous system function \[[@B21-genes-07-00095]\]. One is tempted to speculate that these piRNAs might potentially regulate the expression of the risk genes and serve as functional components of the pathways through which the risk SNPs influence risk for ND/CPD. These hypotheses regarding LncRNAs and piRNAs should be tested in the future.
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ncRNAs
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LncRNAs
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genes-07-00095-t001_Table 1

###### 

Replicated associations between *CHRN* genes and nicotine dependence.

  SNP          Gene             *p*                   Ref.                        *p*               Ref.                        *p*                       Ref.                        *p*                       Ref.                        *p*                      Ref.                        *p*                       Ref.                        *p*                       Ref.                        *p*                    Ref.
  ------------ ---------------- --------------------- --------------------------- ----------------- --------------------------- ------------------------- --------------------------- ------------------------- --------------------------- ------------------------ --------------------------- ------------------------- --------------------------- ------------------------- --------------------------- ---------------------- ---------------------------
  rs10958725   *CHRNB3-A6*      [3.1 × 10]{.ul}^−8^   \[[@B54-genes-07-00095]\]   4.7 × 10^−3^      \[[@B55-genes-07-00095]\]   3.6 × 10^−5^              \[[@B55-genes-07-00095]\]                                                                                                                                                                                                                                                 
  rs10958726   *CHRNB3-A6*      [1.2 × 10]{.ul}^−7^   \[[@B54-genes-07-00095]\]   9.6 × 10^−5^      \[[@B56-genes-07-00095]\]   5.7 × 10^−3^              \[[@B57-genes-07-00095]\]   1.1 × 10^−3^              \[[@B57-genes-07-00095]\]   1.1 × 10^−2^             \[[@B55-genes-07-00095]\]   1.4 × 10^−5^              \[[@B55-genes-07-00095]\]                                                                                
  rs13273442   *CHRNB3-A6*      [1.4 × 10]{.ul}^−7^   \[[@B54-genes-07-00095]\]   2.0 × 10^−2^      \[[@B58-genes-07-00095]\]   1.4 × 10^−3^              \[[@B58-genes-07-00095]\]   3.0 × 10^−2^              \[[@B58-genes-07-00095]\]                                                                                                                                                                                           
  rs4736835    *CHRNB3-A6*      [3.0 × 10]{.ul}^−8^   \[[@B54-genes-07-00095]\]   6.0 × 10^−3^      \[[@B55-genes-07-00095]\]   6.2 × 10^−3^              \[[@B57-genes-07-00095]\]                                                                                                                                                                                                                                                 
  rs1955186    *CHRNB3-A6*      8.3 × 10^−5^          \[[@B56-genes-07-00095]\]   5.4 × 10^−3^      \[[@B57-genes-07-00095]\]   1.1 × 10^−2^              \[[@B57-genes-07-00095]\]                                                                                                                                                                                                                                                 
  rs1955185    *CHRNB3-A6*      [4.6 × 10]{.ul}^−8^   \[[@B54-genes-07-00095]\]   1.0 × 10^−4^      \[[@B56-genes-07-00095]\]   1.1 × 10^−5^              \[[@B55-genes-07-00095]\]   5.4 × 10^−3^              \[[@B57-genes-07-00095]\]   1.2 × 10^−3^             \[[@B57-genes-07-00095]\]                                                                                                                                      
  rs13277254   *CHRNB3-A6*      4.0 × 10^−3^          \[[@B59-genes-07-00095]\]   4.0 × 10^−5^      \[[@B56-genes-07-00095]\]   7.8 × 10^−4^              \[[@B57-genes-07-00095]\]   6.3 × 10^−4^              \[[@B60-genes-07-00095]\]                                                                                                                                                                                           
  rs13277524   *CHRNB3-A6*      6.0 × 10^−5^          \[[@B56-genes-07-00095]\]   3.8 × 10^−3^      \[[@B57-genes-07-00095]\]   7.4 × 10^−4^              \[[@B57-genes-07-00095]\]                                                                                                                                                                                                                                                 
  rs6474412    *CHRNB3-A6*      1.1 × 10^−4^          \[[@B56-genes-07-00095]\]   5.6 × 10^−3^      \[[@B57-genes-07-00095]\]   1.0 × 10^−3^              \[[@B61-genes-07-00095]\]   8.7 × 10^−3^              \[[@B55-genes-07-00095]\]   2.1 × 10^−5^             \[[@B55-genes-07-00095]\]   [\* 1.7 × 10]{.ul}^−4^    \[[@B62-genes-07-00095]\]   [\* 2.6 × 10]{.ul}^−5^    \[[@B62-genes-07-00095]\]   \* 8.0 × 10^−3^        \[[@B63-genes-07-00095]\]
  rs6474413    *CHRNB3-A6*      [3.6 × 10]{.ul}^−8^   \[[@B54-genes-07-00095]\]   6.3 × 10^−5^      \[[@B56-genes-07-00095]\]   9.3 × 10^−4^              \[[@B57-genes-07-00095]\]                                                                                                                                                                                                                                                 
  rs7004381    *CHRNB3-A6*      [9.9 × 10]{.ul}^−8^   \[[@B54-genes-07-00095]\]   3.9 × 10^−2^      \[[@B60-genes-07-00095]\]   3.1 × 10^−3^              \[[@B57-genes-07-00095]\]                                                                                                                                                                                                                                                 
  rs4950       *CHRNB3-A6*      [9.5 × 10]{.ul}^−8^   \[[@B54-genes-07-00095]\]   1.0 × 10^−4^      \[[@B56-genes-07-00095]\]   1.4 × 10^−3^              \[[@B57-genes-07-00095]\]   7.0 × 10^−3^              \[[@B60-genes-07-00095]\]   1.1 × 10^−5^             \[[@B55-genes-07-00095]\]                                                                                                                                      
  rs13280604   *CHRNB3-A6*      [1.0 × 10]{.ul}^−7^   \[[@B54-genes-07-00095]\]   6.0 × 10^−3^      \[[@B60-genes-07-00095]\]   1.4 × 10^−5^              \[[@B55-genes-07-00095]\]   [\* 1.2 × 10]{.ul}^−4^    \[[@B62-genes-07-00095]\]   [\* 2.7 × 10]{.ul}^−5^   \[[@B62-genes-07-00095]\]                                                                                                                                      
  rs4952       *CHRNB3-A6*      4.1 × 10^−3^          \[[@B56-genes-07-00095]\]   1.1 × 10^−2^      \[[@B57-genes-07-00095]\]   1.4 × 10^−3^              \[[@B57-genes-07-00095]\]   2.0 × 10^−2^              \[[@B58-genes-07-00095]\]                                                                                                                                                                                           
  rs4954       *CHRNB3-A6*      4.3 × 10^−7^          \[[@B64-genes-07-00095]\]   6.0 × 10^−3^      \[[@B65-genes-07-00095]\]   4.1 × 10^−3^              \[[@B57-genes-07-00095]\]                                                                                                                                                                                                                                                 
  rs16969968   *CHRNA5-A3-B4*   1.0 × 10^−2^          \[[@B59-genes-07-00095]\]   1.3 × 10^−4^      \[[@B56-genes-07-00095]\]   [\* 2.4 × 10]{.ul}^−69^   \[[@B62-genes-07-00095]\]   [\* 5.6 × 10]{.ul}^−72^   \[[@B66-genes-07-00095]\]   \* 9.0 × 10^−4^          \[[@B67-genes-07-00095]\]   [\* 4.3 × 10]{.ul}^−65^   \[[@B68-genes-07-00095]\]   [5.1 × 10^−17^]{.ul}      \[[@B69-genes-07-00095]\]                          
  rs1051730    *CHRNA5-A3-B4*   2.0 × 10^−4^          \[[@B56-genes-07-00095]\]   2.0 × 10^−3^      \[[@B70-genes-07-00095]\]   [\* 5.8 × 10]{.ul}^−44^   \[[@B68-genes-07-00095]\]   [\* 2.8 × 10]{.ul}^−73^   \[[@B66-genes-07-00095]\]   \* 1.0 × 10^−3^          \[[@B67-genes-07-00095]\]   [\* 1.7 × 10]{.ul}^−66^   \[[@B68-genes-07-00095]\]   [\* 6.0 × 10]{.ul}^−20^   \[[@B71-genes-07-00095]\]   [4.3 × 10]{.ul}^−17^   \[[@B69-genes-07-00095]\]
  rs6495308    *CHRNA5-A3-B4*   1.9 × 10^−3^          \[[@B56-genes-07-00095]\]   \* 6.9 × 10^−5^   \[[@B72-genes-07-00095]\]   4.8 × 10^−3^              \[[@B56-genes-07-00095]\]   [1.7 × 10]{.ul}^−7^       \[[@B69-genes-07-00095]\]                                                                                                                                                                                           
  rs2236196    *CHRNA4*         3.1 × 10^−7^          \[[@B64-genes-07-00095]\]   2.0 × 10^−2^      \[[@B73-genes-07-00095]\]   5.0 × 10^−4^              \[[@B57-genes-07-00095]\]   4.4 × 10^−4^              \[[@B57-genes-07-00095]\]   [2.7 × 10^−2^]{.ul}      \[[@B69-genes-07-00095]\]                                                                                                                                      

*p. p-*value; Ref. reference. \* associations with cigarettes per day (CPD). The associations identified by GWASs were [underlined]{.ul}.

genes-07-00095-t002_Table 2

###### 

Significant expression correlation between *CHRNs* and dopaminergic and GABAergic receptor genes in human brain.

  Genes    *CHRNB3*              *CHRNA6*                        *CHRNA5*         *CHRNA3*                   *CHRNB4*                   *CHRNA4*
  -------- --------------------- ------------------------------- ---------------- -------------------------- -------------------------- -----------------------------------------
  DRD1     SNIG                  PUTM,TCTX                                        FCTX,TCTX                                             FCTX,THAL
  DRD2     SNIG,TCTX             PUTM,SNIG,TCTX,THAL                              FCTX,HIPP,TCTX,THAL        CRBL,FCTX                  CRBL,OCTX,SNIG,TCTX,THAL
  DRD3     FCTX                  PUTM                            THAL             FCTX                       FCTX,OCTX                  
  DRD4     FCTX                                                  THAL             FCTX,TCTX                  FCTX,HIPP,OCTX,PUTM,TCTX   
  DRD5     WHMT                  THAL                            THAL             FCTX,THAL,WHMT             CRBL,FCTX,HIPP,SNIG,WHMT   THAL
  TH       SNIG,TCTX,WHMT        SNIG,TCTX                                        FCTX,TCTX                  CRBL,FCTX,OCTX             CRBL,SNIG
  GABRA1   SNIG                  SNIG,THAL                       SNIG,THAL        CRBL,THAL                  FCTX                       FCTX,HIPP,MEDU,SNIG,THAL
  GABRA2   OCTX                  MEDU,OCTX,PUTM,THAL             CRBL,MEDU        FCTX,MEDU,TCTX,THAL        FCTX,MEDU                  OCTX,THAL
  GABRA3   OCTX,SNIG             MEDU,OCTX,SNIG,THAL             MEDU,SNIG,THAL   CRBL,THAL                                             CRBL,FCTX,HIPP,OCTX,PUTM,SNIG,TCTX,THAL
  GABRA4   FCTX,OCTX,SNIG,THAL   MEDU,OCTX,PUTM,SNIG,THAL,WHMT   CRBL,MEDU,THAL   FCTX,MEDU,TCTX,THAL,WHMT   FCTX,MEDU,TCTX             CRBL,FCTX,HIPP,SNIG,THAL
  GABRA5   OCTX                  MEDU,OCTX,THAL                  MEDU,THAL        MEDU,THAL                  CRBL                       CRBL,FCTX,OCTX,THAL
  GABRA6                                                                          CRBL                                                  
  GABRB1   FCTX,OCTX,PUTM,SNIG   MEDU,PUTM,SNIG,THAL             CRBL,MEDU,SNIG   FCTX,OCTX,TCTX             FCTX,TCTX                  OCTX,SNIG
  GABRB2   SNIG                  SNIG,THAL                       CRBL,THAL        CRBL,FCTX,PUTM,TCTX,THAL   FCTX,TCTX                  FCTX,HIPP,MEDU,THAL
  GABRB3   OCTX,SNIG             MEDU,OCTX,SNIG,THAL             MEDU,THAL        MEDU,TCTX,THAL             MEDU,TCTX                  CRBL,FCTX,OCTX,SNIG,THAL
  GABRD    WHMT                  THAL                            THAL             CRBL,PUTM,THAL,WHMT                                   FCTX,HIPP,MEDU,THAL
  GABRE                          THAL                                                                                                   MEDU
  GABRG1                         MEDU                            CRBL,MEDU        MEDU,OCTX                                             
  GABRG2   OCTX,SNIG,WHMT        SNIG,THAL                       THAL             CRBL,TCTX,THAL             TCTX                       FCTX,HIPP,MEDU,SNIG,THAL
  GABRG3   FCTX                  MEDU,PUTM                       CRBL             TCTX                       FCTX,TCTX                  CRBL,FCTX,MEDU
  GABRP    FCTX,PUTM                                                              FCTX                       CRBL,FCTX,PUTM             
  GABRQ    HIPP                  THAL                            THAL             HIPP,THAL                  CRBL                       CRBL,MEDU,PUTM,THAL
  GABRR2                                                                          THAL                                                  

α = 3.3 × 10^−5^. Cerebellar cortex (CRBL), frontal cortex (FCTX), hippocampus (HIPP), medulla (specifically inferior olivary nucleus, MEDU), occipital cortex (specifically primary visual cortex, OCTX), putamen (PUTM), substantia nigra (SNIG), temporal cortex (TCTX), thalamus (THAL), and intralobular white matter (WHMT). These six CHRN genes were detected in ten human brain areas. In many areas, their expression was significantly correlated with the dopaminergic or GABAergic expression (*p* \< α) ([Table 2](#genes-07-00095-t002){ref-type="table"}). The correlation coefficients (0.358 ≤ \|r\| ≤ 0.920), regression coefficients (0.008 ≤ \|β\| ≤ 0.749) and *p* values (3.9 × 10^−42^ ≤ *p* ≤ 3.3 × 10^−5^) for these correlations are shown in the [Supplementary Tables S1 and S2](#app1-genes-07-00095){ref-type="app"}.

genes-07-00095-t003_Table 3

###### 

*Chrn* gene expression at whole brain and different brain areas of BXD mice.

  Gene       Location (Chr, Mb)   Whole Brain   Cortex         Striatum      NAc           Hippocampus   Amygdala      Midbrain       VTA           Cerebellum
  ---------- -------------------- ------------- -------------- ------------- ------------- ------------- ------------- -------------- ------------- -------------
  *Chrnb3*   Chr8: 28.504645      7.85          7.11                                       7.25                                       [7.65]{.ul}   
  *Chrna6*   Chr8: 28.513939      8.73                                       7.79          7.13                        [10.37]{.ul}   [8.97]{.ul}   7.23
  *Chrna5*   Chr9: 54.852890                    [7.22]{.ul}                                8.44          [7.45]{.ul}                                
  *Chrna3*   Chr9: 54.860390      9.35                                       [7.22]{.ul}   [8.32]{.ul}                                [7.60]{.ul}   [7.61]{.ul}
  *Chrnb4*   Chr9: 54.877893      7.23                         7.58                        8.65          8.18          8.23                         
  *Chrna4*   Chr2: 180.759407     9.48          [10.05]{.ul}   [9.02]{.ul}   [8.29]{.ul}   9.95          10.73         9.64           [8.71]{.ul}   8.30

The order of the gene list corresponds to [Table 1](#genes-07-00095-t001){ref-type="table"}. Only the standardized expression values (SEV) \> 7 are listed. The expression replicating the previous reports ([Figure 1](#genes-07-00095-f001){ref-type="fig"}) is underlined. This is a sub-table of the [Table 5](#genes-07-00095-t005){ref-type="table"} in the paper by Zuo et al. \[[@B3-genes-07-00095]\].

genes-07-00095-t004_Table 4

###### 

*Cis*-acting expression of quantitative locus (*cis*-eQTL) analysis.

  SNPs         Target gene   Cerebellar Cortex   Frontal Cortex   Temporal Cortex   Occipital Cortex   Putamen        Thalamus       Hippo-Campus   Substantia Nigra   Intralobular White Matter   Medulla
  ------------ ------------- ------------------- ---------------- ----------------- ------------------ -------------- -------------- -------------- ------------------ --------------------------- --------------
  rs10958725   *CHRNB3*      0.015                                                                                    0.026                                                                        
  rs10958725   *CHRNA6*                          0.042                                                                               0.027                                                         
  rs10958726   *CHRNB3*      0.020                                                                                    0.028                                                                        
  rs10958726   *CHRNA6*                          0.043                                                                               0.031                                                         
  rs13273442   *CHRNB3*      0.022                                                                                    0.030                                                                        
  rs13273442   *CHRNA6*                          0.043                                                                               0.032                                                         
  rs4736835    *CHRNB3*      0.022                                                                                    0.030                                                                        
  rs4736835    *CHRNA6*                          0.043                                                                               0.032                                                         
  rs1955186    *CHRNB3*      0.022                                                                                    0.030                                                                        
  rs1955186    *CHRNA6*                          0.043                                                                               0.032                                                         
  rs1955185    *CHRNB3*      0.022                                                                                    0.030                                                                        
  rs1955185    *CHRNA6*                          0.043                                                                               0.032                                                         
  rs13277254   *CHRNB3*      0.021                                                                                    0.031                                                                        
  rs13277254   *CHRNA6*                          0.042                                                                               0.033                                                         
  rs13277524   *CHRNB3*      0.022                                                                                    0.030                                                                        
  rs13277524   *CHRNA6*                          0.043                                                                               0.032                                                         
  rs6474412    *CHRNB3*      0.022                                                                                    0.030                                                                        
  rs6474412    *CHRNA6*                          0.043                                                                               0.032                                                         
  rs6474413    *CHRNB3*      0.022                                                                                    0.030                                                                        
  rs6474413    *CHRNA6*                          0.043                                                                               0.032                                                         
  rs7004381    *CHRNB3*      0.022                                                                                    0.030                                                                        
  rs7004381    *CHRNA6*                          0.043                                                                               0.032                                                         
  rs4950       *CHRNB3*      0.022                                                                                    0.030                                                                        
  rs4950       *CHRNA6*                          0.043                                                                               0.032                                                         
  rs13280604   *CHRNB3*      0.022                                                                                    0.030                                                                        
  rs13280604   *CHRNA6*                          0.043                                                                               0.032                                                         
  rs16969968   *CHRNA5*      0.034               2.0 × 10^−4^     9.3 × 10^−5^      5.1 × 10^−6^       1.9 × 10^−3^   2.2 × 10^−3^   5.9 × 10^−5^   1.8 × 10^−5^       0.016                       1.6 × 10^−4^
  rs16969968   *CHRNA3*                                                                                8.9 × 10^−4^                                                                                
  rs1051730    *CHRNA5*      0.034               2.0 × 10^−4^     9.3 × 10^−5^      5.1 × 10^−6^       1.9 × 10^−3^   2.2 × 10^−3^   5.9 × 10^−5^   1.8 × 10^−5^       0.016                       1.6 × 10^−4^
  rs1051730    *CHRNA3*                                                                                8.9 × 10^−4^                                                                                
  rs6495308    *CHRNA5*      5.1 × 10^−3^        1.9 × 10^−4^     4.2 × 10^−3^      8.4 × 10^−3^       2.8 × 10^−4^                  1.6 × 10^−4^   7.3 × 10^−3^       3.4 × 10^−3^                
  rs6495308    *CHRNA3*                                                                                2.7 × 10^−3^                                                                                0.013
  rs6495308    *CHRNB4*                                                             0.025                                                                                                          0.014
  rs2236196    *CHRNA4*                                                                                                                                                0.044                       0.035

α = 2.8 × 10^−4^ = 0.05/(10 brain tissues × 6 genes × 3 haplotype blocks); *n* = 134.

genes-07-00095-t005_Table 5

###### 

Bioinformatics analyses on replicable risk *CHRN* SNPs.

  SNP                      Chr   Position   Location             Allele Frequency   2^nd^ RNA Alteration   Bioinformatics                                
  ------------------------ ----- ---------- -------------------- ------------------ ---------------------- ---------------- ------- -------------------- -----------------------------------------
  rs10958725               8     42524584   5′ to CHRNB3         G                  0.822                  0.239            0.792   Highly significant   \--
  rs10958726               8     42535909   5′ to CHRNB3         T                  0.807                  0.328            0.816   no                   \--
  rs13273442               8     42544017   5′ to CHRNB3         G                  0.825                  0.35             0.826   Significant          \--
  rs4736835                8     42547033   5′ to CHRNB3         C                  0.825                  0.35             0.826   Significant          LncRNA
  rs1955186                8     42549491   5′ to CHRNB3         C                  0.833                  0.326            0.875   Mild                 TFBS, LncRNA
  rs1955185                8     42549647   5′ to CHRNB3         T                  0.822                  0.233            0.836   no                   TFBS, LncRNA
  rs13277254               8     42549982   5′ to CHRNB3         A                  0.833                  0.435            0.875   no                   TFBS, LncRNA
  rs13277524               8     42550057   5′ to CHRNB3         T                  0.833                  0.326            0.875   Significant          TFBS, LncRNA
  rs6474412                8     42550498   5′ to CHRNB3         T                  0.81                   0.309            0.824   Significant          TFBS, LncRNA
  rs6474413                8     42551064   5′ to CHRNB3         T                  0.833                  0.235            0.875   no                   TFBS, LncRNA
  rs7004381                8     42551161   5′ to CHRNB3         G                  0.825                  0.339            0.826   Mild                 TFBS, LncRNA
  rs4950                   8     42552633   5′UTR of CHRNB3      A                  0.828                  0.182            0.826   no                   TFBS, LncRNA
  rs13280604               8     42559586   Intron 1 of CHRNB3   A                  0.825                  0.178            0.826   no                   LncRNA
  rs4952                   8     42587065   Exon 6 of CHRNB3     C                  0.983                  1                1       Highly significant   \--
  rs4954                   8     42587796   Intron 6 of CHRNB3   A                  0.973                  0.773            0.885   no                   chromatin
  rs16969968 (Asp398Asn)   15    78882925   Exon 5 of CHRNA5     G                  0.587                  1                0.982   Highly significant   splicing,tolerated, benign,conservative
  rs1051730                15    78894339   Exon 7 of CHRNA3     G                  0.608                  0.876            0.982   no                   CpG
  rs6495308                15    78907656   Intron 6 of CHRNA3   T                  0.792                  0.661            0.244   no                   \--
  rs2236196                20    61977556   3′UTR of CHRNA4      A                  0.744                  0.458            0.889   no                   chromatin

2nd RNA alteration, the alteration of secondary RNA structure predicted using MFOLD; LncRNA, these SNPs are located in LncRNAs; TFBS, these SNPs are located in the transcription factor binding sites; chromatin, this SNP is located in an open chromatin region; splicing, this SNP is located in an exonic splicing silencer or enhancer; tolerated/benign, these SNPs are predicted by SIFT/Polyphen not to significantly affect protein function or structure; conservative, this SNP is predicted to be conservative; CpG, this SNP is located within a 234 bp methylated CpG island.

genes-07-00095-t006_Table 6

###### 

The long non-coding RNAs (LncRNAs) proximate to the three replicable *CHRN* genes.

  LncRNA name (NCBI Gene)   Alias          Length (nt)   Distance to risk gene             Category
  ------------------------- -------------- ------------- --------------------------------- --------------------------
  XR_949716.1               LOC105379396   21,176        Covering *CHRNB3*                 antisense LncRNA
  XR_932509.1               LOC105370913   35,230        37,240 bp to *CHRNB4*             intergenic sense LincRNA
  NR_110634.1               LOC100130587   11,190        Overlap with exon 1 of *CHRNA4*   antisense LncRNA

Intergenic, located between two protein-coding genes and at least 1 kb away from these genes; Sense, LncRNAs are transcribed from the same genomic strand as the protein-coding mRNAs; Antisense, LncRNAs are transcribed from the antisense strand.
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###### 

The annotated piRNAs within the two replicable *CHRN* genes.

  Replicable genes   Position (Build 37)        Number of piRNAs   Length (nt)
  ------------------ -------------------------- ------------------ -------------
  *CHRNB3*           chr8:42552561--42592208    42                 26--31
  *CHRNA6*           chr8:42607762--42623618    8                  29--31
  *CHRNA5*           chr15:78857905--78886459   17                 28--31
  *CHRNA3*           chr15:78887650:78913321    20                 26--31
  *CHRNB4*           Chr15:78916635:78933586    4                  27--29
